CD80 Protein (CD80) (His tag)

Catalog No. ABIN7668401

This Recombinant CD80 protein is expressed in Escherichia coli (E. coli).

Quick Overview for CD80 Protein (CD80) (His tag) (ABIN7668401)

Target: CD80

Protein Type: Recombinant

Biological Activity: Inactive

Origin: Rat

Source: Escherichia coli (E. coli)

Purity: > 95 %

Product Details

Purification tag / Conjugate: This CD80 protein is labelled with His tag.

Purpose: Recombinant Rat CD80/B7-1 protein (His tag)

Sequence: Gly 41-Ala 262

Purification: > 95 % as determined by reducing SDS-PAGE.

Sterility: 0.2 μm filtered

Endotoxin Level: < 10 EU/mg of the protein as determined by the LAL method.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Buffer: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % -8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Expiry Date: 12 months

Target Details

Target: CD80

Alternative Name: CD80,B7-1

Background: The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.,Activation B7-1 antigen,B7,CD80,Cd28l,Ly-53,Ly53,MIC17,T-lymphocyte activation antigen CD80,TSA1

Molecular Weight:

calculated_mw: 24.3 kDa

observed_mw: 32 kDa

UniProt: G3V671

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints